Introduction
Breast cancer is a worldwide health problem threatening females. According to GLOBOCAN 2008 statistics, Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females, accounting for 23% of the total cancer cases and 14% of the cancer deaths [
1]. Multiple factors, including genetic background, hormone disorder, and environmental impact are involved in breast cancer pathogenesis [
2]. Current evidence shows that various genes contribute to breast cancer biological behavior and clinical phenotypes. It is reported that breast tumorigenesis is strongly associated with aberrant function of genes such as
HER-2/neu,
BRCA1 and
CyclinD1[
3], which could be manipulated by gene expression level and/or gene mutation/rearrangement. In fact, dysregulation of gene expression, such as activation of oncogenes or inactivation of tumor-suppressor genes, are frequently reported to trigger breast cancers [
4]. Genomics also elucidates that multiple gene mutations/rearrangements exist in breast cancers [
5,
6]. Therefore, multiple genes are involved in breast tumorigenesis. Further illustration of breast cancer pathogenesis is critical for disease treatment and prevention.
Recent discoveries of histone demethylases have advanced our understanding of transcriptional regulation [
7‐
9]. Histone demethylases are enzymes that catalyze demethylation of lysine residues (mainly H3K4, H3K9, H3K27, H3K36 and H4K20) located in the N-terminal tails of histones. Based on recent findings, methylation of H3K9, H3K27 and H4K20 is mainly associated with repressive transcription whereas methylation of H3K4 and H3K36 mainly activates transcription [
10]. Thus demethylation of different lysine residues may result in activated or repressed transcription. Jumonji domain containing 2A (JMJD2A, also known as JHDM3 or KDM4A) is a member of JmjC domain containing family JMJD2 that catalyzes histone demethylation. Due to its activity to demethylate di-and tri-methylation on a variety of histone lysine residues, such as H3K9 and H3K36 [
11], H3K4 and H4K20 [
12,
13], JMJD2A can modify chromatin structure and function as a transcriptional repressor or activator. Previous report indicated that JMJD2A significantly demethylates tri- and di-methylated, but not monomethylated H3K36 and H3K9
in vivo[
14]. Recent evidence shows that JMJD2A positively regulates the expression of
ADAM12,
CXCL5 and
JAG1 genes through histone H3K9me3 demethylation [
15]. Furthermore, it was observed that H3K9me3 levels are increased at
ASCL2 and
CHD5 gene promoters after depletion of JMJD2A [
16,
17]. JMJD2A is widely expressed in diverse cancers, including lung carcinoma, colon cancer and breast cancer [
17‐
20]. In addition to its enzymatic activity, JMJD2A protein contains both leukemia-associated protein/plant homeodomain (LAP/PHD) and Tudor domains which were implicated protein-protein interactions. Functionally, JMJD2A could interact with histone deacetylase (HDAC) and retinoblastoma protein (pRb) and could direct repression of E2F-responsive promoters [
21]. JMJD2A is also reported to be a novel N-CoR interacting protein, leading to transcriptional repression of downstream genes like
ASCL2 [
16].
Aplasia Ras homolog member I (ARHI) is a Ras-related small G-protein with a low guanosine triphosphate (GTP) enzymatic activity and Mg
2+-dependence [
22,
23]. Unlike other small GTP-binding proteins, ARHI exhibits functional repression of cell growth and functions as a tumor suppressor. ARHI is highly expressed in normal breast and ovarian tissues, but repressed in breast and ovarian cancers [
24,
25], indicating that ARHI dysfunction is closely related with tumorigenesis and progression. In fact, overexpression of ARHI leads to retarded proliferation [
26,
27], migration [
28], and invasion [
27,
28] in breast cancer. ARHI could restrict migration of non-cancer cells through interaction with C-RAF to suppress the activating phosphorylations on mitogen-activated protein kinase kinases (MEK) and extracellular signal-regulated kinase (ERK). And knockdown of ARHI could reverse the effect [
29]. ARHI could also suppress ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways [
30]. Like other tumor suppressors, ARHI expression could be regulated by deletion of an allele and promoter methylation [
31], transcriptional factors and HDAC-containing complexes [
32,
33]. E2F1 and E2F4 are reported to negatively regulate ARHI expression by forming complex with HDAC. Overexpression of E2F1 and E2F4 could negatively regulate
ARHI promoter activity [
33], and multiple HDACs such as HDAC1, 3 and 11 are identified to negatively regulate
ARHI expression [
32].
Previously, we reported that knockdown of JMJD2A expression could slow down cell proliferation, migration and invasion in both MCF-7 and MDA-MB-231 cells [
34,
35]. However, the regulatory mechanisms remain unclear. In addition to
ASCL2 gene, JMJD2A was shown to transcriptionally repress other genes, such as the tumor suppressor gene
CHD5 in a lung carcinoma model [
17]. In this study, we report that JMJD2A promotes breast cancer progression through transcriptional repression of the tumor suppressor ARHI. We found that JMJD2A correlates with breast cancer progression and promotes breast cancer progression through transcriptional silencing of
ARHI. The repression of ARHI expression by JMJD2A required the involvements of E2Fs and HDACs, and the aggressive behavior of JMJD2A could be reversed by re-expression of ARHI both
in vitro and
in vivo. In all, we defined a molecular pathway contributing to JMJD2A-mediated breast cancer progression.
Materials and methods
Ethics statements
Permission to use human tissue sections for research purposes was obtained and approved by an institutional review board at Huashan Hospital, Shanghai, China. All patients provided their full consent to participate in our study. For animal research, the protocol was approved by the Ethics Committee from Shanghai Medical College, Fudan University, China. And all efforts were made to minimize suffering.
Cells and reagents
Breast cancer cell lines MCF-7, T47D, SUM1315 and MDA-MB-231 were purchased from ATCC (Manassas, VA, USA) and cultured in DMEM (Hyclone, Logan, Utah, USA) supplemented with 10% FBS (Gibco, Los Angeles, CA, USA). Primary antibodies against JMJD2A (C37E5), E2F1 (3742), HDAC1 (5356) and HDAC3 (3949) were purchased from Cell Signaling Technology (Boston, MA, USA). Anti-estrogen receptor alpha (anti-ERα) (ab2746), anti-progesterone receptor (PR) (ab32085), anti-human epidermal growth factor receptor-2 (anti-HER2) (ab134182), anti-E2F4 (ab150360) and anti-ARHI (ab107051) primary antibodies were all obtained from Abcam (Cambridge, UK). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody (sc-25778) was purchased from Santa Cruz (CA, USA). Lipofectamine 2000 was purchased from Invitrogen (Carlsbad, CA, USA). Trichostatin A (TSA) was purchased from Sigma Co. (St Louis, MO, USA). The chromatin immunoprecipitation (ChIP) kit was purchased from Upstate (a part of Millipore, Billerica, MA, USA). For the co-immunoprecipitation (Co-IP) assay, the protein G agarose beads and NP-40 lysis buffer were purchased from Beyotime Institute of Biotechnology (Nantong, China). Matrigel was purchased from BD Biosciences (San Jose, CA, USA). Cell counting kit-8 (cck-8) was purchased from Dojindo (Japan). And dual-luciferase reporter gene assay were from Promega (Madison, WI, USA).
Plasmids and siRNAs
JMJD2A expression plasmid was subscribed by Dr Ralf Janknecht from the Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Dr Hsing-Jien Kung, Deputy Director and Director of Basic Science, UC Davis Cancer Center. JMJD2A (NM_014663.2) was PCR-amplified from the subscribed plasmids and cloned into pcDNA3.1 vetors (pcDNA3.1-JMJD2A). ARHI (AY890085.1) was amplified on mRNA from MCF-7 cells and cloned into pcDNA3.1 vetors (pcDNA3.1-ARHI) as per the molecular cloning manual. siRNA specific to JMJD2A was chemically synthesized by Qiagen Technology Co. Ltd (Valencia, CA, USA). siRNA was diluted to 20 μmol/L with RNase-free water. siRNA duplexes were synthesized as follows: sense: 5′-GAGUUAUCAACUCAAGAUA-3′, antisense:5′-UAUCUUGAGUUGAUAACUC-3′. The other two JMJD2A siRNAs were synthesized by GenePharma (Shanghai, China) with the sequences described previously [
15]. siRNAs specific to E2F1 and E2F4 were also synthesized by GenePharma (Shanghai, China) with sequences verified and described previously [
36,
37]. Scramble siRNA was used as negative control (NC) and sequences were as follows: sense: UUCUCCGAACGUGUCACGU, antisense: ACGUGACACGUUCGGAGAATT. Plasmids and siRNAs were transfected with Lipofectamine 2000 in accordance with the manufacturer’s instructions.
Patients and histological and immunohistochemical (IHC) staining
All the 155 cases of breast cancer and 30 cases of non-neoplastic tissues were retrieved from the Department of Pathology, Huashan Hospital, Shanghai, China, within 2012. All cases were diagnosed by two experienced pathologists without discrepancy. None of the patients had received chemotherapy or radiation therapy previously. The paraffin-embedded tissues were first stained with hematoxylin and eosin (HE) for histological examination. Subsequently, sections were subjected to antigen retrieval by heating the slides in a microwave at 100°C for 10 minutes in 0.1-M citric acid buffer (PH 6.0), and then incubated with corresponding antibodies at 4°C overnight. After secondary antibody incubation at room temperature for 1 h, the slides were developed in 0.05% diaminobenzidine containing 0.01% hydrogen peroxidase. For negative controls, specific antibodies were replaced with normal goat serum by co-incubation at 4°C overnight preceding the immunohistochemiscal staining procedure.
Western blot analysis
At 48 h after transfection, cells in different treatment groups were harvested. The procedure was used as described previously [
38,
39]. Antibodies against JMJD2A, ARHI, GAPDH, E2F1, and E2F4 were used to incubate target proteins overnight at 4°C. After the overnight incubation with the primary antibodies, membranes were washed and incubated with horseradish peroxidase (HRP)-labeled secondary antibody in Tris-buffered saline with Tween 20 (TBST) for 1 h. Immunoreactivity was detected with enhanced chemoluminescent autoradiography (ECL kit, Amersham, Pittsburgh, PA, USA), according to the manufacturer’s instruction. GAPDH was used as a loading control.
Quantitative real-time PCR (qPCR)
Total RNA of each group were extracted respectively using Trizol solution (Invitrogen) at 24 h after transfection. Fast-strand cDNA was generated from 1 μg of total RNA using the PrimeScript RT Master Mix Perfect Real Time (TaKaRa, Shiga, Japan). Real-time qPCR was performed in an ABI PRISM 7500 Real-Time System. A 10-fold dilution of each cDNA was amplified in a 50 μl volume, using the SYBR Premix Ex TaqTM Perfect Real Time (TaKaRa, Shiga, Japan). The primers used were as follows: JMJD2A: forward 5′-ATCCCAGTGCTAGGATAATGACC-3′, reverse 5′-ACTCTTTTGGAGGAACCCTTG-3′; ARHI: forward 5′-GATTACCGCGTCGTGGTAGTC-3′, reverse 5′-TCAATGGTCGGCAGGTACTCA-3′; GAPDH: forward, 5′-TGACGCTGGGGCTGGCATTG-3′, reverse 5′-GCTCTTGCTGGGGCTGGTGG-3′.
Primers were synthesized by Shanghai Daweike Biotechnology Co. Ltd (Shanghai, China). PCR cycle conditions were 95°C for 30 s, and 40 cycles of 95°C for 5 s and 60°C for 34 s. The amplification specificity was evaluated with melting curve analysis. Relative mRNA was determined by using the formula 2
-ΔCT (CT, cycle threshold) where, as described previously [
40]:
Dual luciferase reporter assay
HEK293T cells were seeded at a density of 2 × 10
5/well in 24-well plates and co-transfected with indicated amounts of ARHI/luciferase reporter together with the full-length JMJD2A construct (JMJD2A-FL), the construct of JMJD2A with the substitution of histidine 188 by alanine (JMJD2A-H188A), or another construct of JMJD2A with the deletion of the tudor domains (JMJD2A-M867) [
21,
41]. Renilla luciferase plasmid (pRL) was co-transfected as internal control. Thirty-six hours after transfection, cells were lysed using passive lysis buffer and assayed immediately for reporter and control gene activities with the dual-luciferase reporter gene assay using a Lumat LB 9507 luminometer (EG & G Berthold, Bad Wildbad, Germany). To determine the effect of HDACs, cells were treated with or without 100 nM trichostatin A (TSA) at 12 h after transfection. Each experiment was performed in triplicate, and the data represent three independent experiments after normalization to renilla activity.
Chromatin immunoprecipitation (ChIP) assay
Briefly, lysates were incubated with 4 μg of anti-JMJD2A antibody or normal rabbit IgG as a negative control. PCR amplification was performed using 1:100 dilution of input, an IgG negatively immunoprecipitated DNA and specific JMJD2A immunoprecipitated DNA. In general, samples were heated at 95°C for 3 minutes, followed by 31 cycles of 95°C for 30 s, 54°C for 30 s and 72°C for 20 s. After cycling, samples were incubated at 72°C for 10 minutes to permit completion of primers extension. Then PCR products were electrophoresed on a 2% agarose gel with ethidium bromide. The two pairs of ARHI primers (A1, A2) were as follows: A1 (−181 to 91) forward: 5′-TCGATTGTTGTAGATGCCAAG-3′, reverse: 5′-AGACTTACCTTTCTCGGAGGC-3′; A2 (−524 to −341), forward: 5′-TTTACCGGTCTTGCCACTAATG-3′, reverse: 5′-TCCAAAAGCAGTTTAATGCAGG-3′. GAPDH was used as a loading control (154 bp).
Co-immunoprecipitation (Co-IP) assay
MDA-MB-231 cell lysates were obtained using NP-40 lysis buffer. Specific antibodies were used for immunoprecipitation as well as 20 μl of protein G agarose beads. The beads were washed in lysis buffer and boiled in 30 μl of SDS loading buffer; the entire sample was loaded on a SDS-polyacrylamide gel and processed by western blot. The membranes were immunoblotted with corresponding primary antibodies. Rabbit normal IgG was used as negative control.
CCK-8 proliferation assay
Cells were seeded on 96-well plates at an initial density of 4 × 103/well. At each monitored time point, cells of each well were stained with 10 μl CCK-8 (Dojindo, Japan) for 4 h at 37°C. Absorbance was measured using a synergy 2 multi-mode microplate reader (Bio Tek Instruments, Winooski, VT, USA) at 450 nm. All experiments were carried out in triplicate.
Wound-healing assay and Boyden chamber assay
A wound-healing assay and Boyden chamber assay were performed as described previously [
42]. Cells were plated on 6-well plates to form a confluent monolayer. Wounds made with sterile pipette tips were observed per 12 h. A migration assay was carried out using Boyden chambers (tissue culture-treated, 6.5-mm diameter, 8-μm pores, Transwell, Costar, Cambridge, MA, USA) containing polycarbonate membrane. For the invasion assay, 50 μl matrigel (BD Biosciences, San Jose, CA, USA) was used to mimic basement membrane. Briefly, 100 μl of 1 × 10
6 cells in serum-free medium was added to the upper chamber and 600 μl of appropriate medium with 10% FBS was added to the lower chamber. Cells were incubated for 12 h. Migration cells on the under-surface of the membrane were fixed and stained with Giemsa for 10 minutes at room temperature. Photographs of five random regions were taken and the number of cells was counted to calculate the average number of migrated cells per plate.
Mouse xenograft breast cancer models
Five-week-old female athymic nude mice (BALB/c
nu/nu) were used for the experiment. Cells stably expressing JMJD2A or both JMJD2A and ARHI were constructed as previously described [
43]. Cells (1 × 10
6) were injected subcutaneously into the mammary fat pad of the mice. Mice were randomized (n = 7 per group) and assigned to specific groups. Tumor diameters were measured twice a week and tumor volumes (TV) were calculated using the formula as described [
44]:
On day 27 after tumor cell injection, the mice were sacrificed and the excised tumors were measured and weighed. Lung and liver metastatic nodules were also calculated.
Statistical analysis
All values are expressed as mean ± SD. The Student’s t-test and Spearman correlation analysis were used to evaluate the experimental data. P <0.05 was considered statistically significant.
Discussion
JMJD2A is involved in diverse cancers, including lung carcinoma [
17], colon cancer [
19] and breast cancer [
18,
20]. We previously found that mRNA level of JMJD2A is negatively correlated to that of the tumor suppressor ARHI in breast cancer [
20]. Here, we demonstrated a breast cancer-promoting effect of JMJD2A and the regulatory mechanism of ARHI expression by JMJD2A.
Recently, numerous HDAC-containing repression complexes have been identified [
32,
33,
45‐
49]. Among them, E2F-HDAC repressor is characterized as an important one. Here we demonstrated that transcriptional repression of ARHI by JMJD2A requires the involvement of E2F and HDAC. ARHI was downregulated by JMJD2A at both protein and mRNA level. And
ARHI promoter activity was significantly inhibited by JMJD2A, indicating a transcriptional repression of
ARHI by JMJD2A. Current evidence shows that JMJD2A could interact with HDAC (mainly HDAC1 and HDAC3) and pRb [
21]. E2F1 and E2F4 could mediate repression of
ARHI promoter activity on the identified binding site (A2: −524 to −341) together with HDAC and/or pRb, respectively [
33]. ChIP assay suggested that JMJD2A could immunoprecipitate the A2 site of the
ARHI promoter (Figure
4E). Co-IP assay revealed the interactions of JMJD2A with E2F1, E2F4, HDAC1 and HDAC3 (Figure
5A). Furthermore, knockdown of E2F1 and/or E2F4 significantly suppressed the recruitment of JMJD2A to the A2 site in the
ARHI promoter (Figure
6B). Therefore, JMJD2A could form a complex with E2Fs and HDACs to repress the
ARHI promoter activity. Additionally, multiple HDACs (mainly HDAC1 and HDAC3) are also reported to directly or indirectly bind to the
ARHI promoter at the site from −181 to 91 (A1) [
32]. Inhibition of HDAC activity by TSA treatment significantly increased
ARHI promoter activity (Figure
6C). However, as revealed by analysis of
ARHI promoter sequence, only transcription factors like Sp1 and PEA3 were specifically predicted to bind
ARHI promoter site from −181 to 91 [
50]. HDAC could not specifically bind to the A1 site in the
ARHI promoter. We speculate that there might be other transcription factors such as Sp1, PEA3 which forms a complex with JMJD2A and HDACs at the A1 site. Collectively, binding of JMJD2A to the
ARHI promoter is E2F- and HDAC-dependent. Moreover, ARHI re-expression reversed JMJD2A-induced tumor progression
in vitro (Figure
7) and
in vivo (Figure
8), which in turn corroborated our results that JMJD2A promotes breast cancer progression through transcriptional repression of the tumor suppressor ARHI. Taken together, we defined a novel gene regulated by JMJD2A in breast cancer.
Intriguingly, ERα was not observed to significantly correlate with JMJD2A (
P = 0.778). As a member of the same family, JMJD2B was reported to interact with ERα and SWI/SNF-B complex upon estrogen stimulation and lead to ERα target genes activation [
51]. In this process, JmjC catalytical domain, a structure harbored by both JMJD2A and JMJD2B, is crucially required. Thus, JMJD2A was thought to participate in breast cancer onset through the ERα signaling pathway. However, the report further showed that depletion of JMJD2A caused only a marginal defect in ERα target gene induction, indicating that JMJD2A interaction with ERα was not robust. These results are in line with our findings.
The identification of
ARHI as a gene regulated by JMJD2A is of biological significance. JMJD2A was reported to transcriptionally repress
ASCL2
in vitro[
16,
17] and
CHD5 in lung carcinoma [
17]. Genes regulated by JMJD2A in breast cancer have not been reported. Our report may extend the list of downstream genes regulated by JMJD2A. Moreover, the tumor suppressor ARHI is frequently downregulated in breast cancers [
22‐
25]. Here we further demonstrated the regulatory network contributing to ARHI inactivation in breast cancers.
The effect of chromatin structure on gene transcription is determined, at least in part, by the posttranscriptional modifications of the histones, such as acetylation and methylation [
52]. Acetylation is believed to facilitate transcription whereas deacetylation reverses such effects and thus, reinforces the repressive effect of chromatin [
52]. As histone deacetylase, HDAC possibly plays key roles in the repression of transcription. Our results showed that inhibition of ARHI promoter activity by JMJD2A required the involvement of HDAC. In fact, HDAC has functional links to histone acetylation and mediates
ARHI repression [
32]. In contrast, histone demethylation might not be required. Similar to JMJD2A-FL, JMJD2A-H188A could also repress
ARHI promoter activity. Moreover, JMJD2A contains LAP/PHD and Tudor domains, which are implicated in protein-protein interactions [
21]. In this way, JMJD2A could recruit co-regulators, such as pRb, E2F and HDAC. Actually, deletion of Tudor domains impaired JMJD2A-mediated repression of
ARHI promoter activity (Figure
6C). It is possible that JMJD2A loses the ability to bind to promoters or to recruit the regulatory factors after deletion of the Tudor domains.
One interesting observation is the significant liver instead of lung metastasis in the xenograft model. Metastasis is common in malignant tumors. The liver represents a common site of metastasis for solid cancers and the third most common site for breast cancer metastasis [
53]. The metastatic cascade consists of numerous steps, in which interactions between primary tumor cells and resident cells represent the most important factors determining to which organs tumors metastasize [
54,
55]. The importance of cancer cell-hepatocyte interactions was reinforced by the observation that colorectal cancer cells also interact with hepatocytes when metastasizing to liver [
56,
57]. As adhesion molecules such as claudin-2 are reported to promote breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes [
58,
59], we speculate that there must be other molecules regulated by JMJD2A that mediate breast cancer preferably liver metastasis. Further studies will be required to understand the mechanism.
Collectively, JMJD2A promotes breast cancer progression through transcriptional repression of the tumor suppressor ARHI. Of note, JMJD2A was predicted to be a transcriptional repressor and activator [
17]. Here we elucidate JMJD2A as a transcriptional repressor of tumor suppressor ARHI. Genes transcriptionally activated by JMJD2A in breast cancer may also potentially exist. Other genes repressed/activated by JMJD2A in breast cancer remain to be exploited.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LLL and AMX performed the western blot, qPCR, proliferation assay, wound-healing assay and Boyden chamber assay and drafted the whole manuscript. BXL and YWS contributed to the ChIP assay, Co-IP assay and statistical analysis. CLL and YHL carried out the in vivo studies. MCZ, JQJ and ZDX prepared tissue sections and participated in IHC analysis. JHX designed the whole study and carried out the dual luciferase reporter assay. ZQZ conceived of the study and revised the manuscript. All authors read and approved the final manuscript.